BCM
GMAB icon

Bayesian Capital Management’s Genmab GMAB Stock Holding History

Bayesian Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,436
Closed -$342K – 886
2024
Q1 		$342K Buy
+11,436
New +$336K 0.03% 523
2023
Q1 		– Sell
-12,466
Closed -$528K – 905
2022
Q4 		$528K Buy
+12,466
New +$514K 0.08% 345
2022
Q2 		– Sell
-11,964
Closed -$433K – 894
2022
Q1 		$433K Buy
+11,964
New +$411K 0.06% 414

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bayesian Capital Management's GMAB Position: Q2 2024 in Review

Bayesian Capital Management sold out of Genmab (GMAB) in Q2 2024, closing a stake of 11,436 shares — an estimated $342K sold.

Bayesian Capital Management first reported a position in GMAB in Q1 2022 and held it in 3 quarters. The position peaked at $528K in Q4 2022. 219 funds tracked by Wall St. Rank hold GMAB as of Q2 2024.

  • Bayesian Capital Management reported no remaining Genmab position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 11,436 Genmab shares in Q2 2024, an estimated $342K.
  • Bayesian Capital Management first reported a position in Genmab in Q1 2022 and held it in 3 quarters.
  • Bayesian Capital Management's Genmab position peaked at $528K in Q4 2022.
  • 219 funds tracked by Wall St. Rank held Genmab as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.